This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating AWBAT-D Versus the Standard of Care of Split-thickness Skin Graft Donor Sites

This study has been withdrawn prior to enrollment.
(P.I decided to prematurely end this study.)
Information provided by (Responsible Party):
Christopher Attinger, M.D., Georgetown University Identifier:
First received: December 1, 2010
Last updated: December 14, 2016
Last verified: December 2016
Use of AWBAT-D on split thickness skin graft sites will reduce healing time and pain level.

Condition Intervention Phase
Healing of Donor Site Pain Level Device: AWBAT-D Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Prospective, Pilot Study Evaluating a Temporary Skin Substitute (AWBAT-D) Versus the Standard of Care in the Postoperative Treatment of Split-thickness Skin Graft Donor Sites

Further study details as provided by Christopher Attinger, M.D., Georgetown University:

Primary Outcome Measures:
  • Time for donor site to heal with AWBAT-D [ Time Frame: 6 weeks ]
    As compared to current standard of care, Tegaderm.

Secondary Outcome Measures:
  • Pain at donor site [ Time Frame: 6 weeks ]
    Pain at donor site is less than that of standard of care treatment, Tegaderm.

Enrollment: 0
Study Start Date: September 2010
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control
Treatment with Tegaderm
Device: AWBAT-D
Application of AWBAT-D bioengineered device
Experimental: AWBAT-D
Application of AWBAT-D on donor site.
Device: AWBAT-D
Application of AWBAT-D bioengineered device

Detailed Description:
The study is designed as a randomized-controlled trial to examine split thickness skin graft donor wound site healing using AWBAT-D compared to current standard of care: Tegaderm. This will involve randomizing subjects to treatment with the AWBAT-D dressing or Tegaderm and monitoring outcomes. The AWBAT-D device has collagen and we hypothesize that the wounds treated with it will heal faster and with a decreased pain level. The purpose of this study is to evaluate if there are differences in outcomes between AWBAT-D and Tegaderm in healing split thickness skin graft donor sites.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subject is 18 years of age or older
  2. Subjects requiring a split-thickness skin graft with a wound size between 5 and 50cm2 and a depth between 12-18um.
  3. Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study.

Exclusion Criteria:

  1. Subjects < 18 years of age
  2. Subjects with an allergy to porcine products.
  3. Subjects undergoing STSG with a wound size less than 5 cm2 or greater than 50cm2.
  4. Subjects undergoing STSG with a wound depth of less than 12um or greater than 18um.
  5. Subjects undergoing repeat skin graft harvesting at the same donor site.
  6. Has active malignant disease of any kind. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
  7. Subjects participating in any other trials involving the split-thickness skin graft donor site.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01252836

United States, District of Columbia
Georgetown University Hospital Center for Wound Healing
Washington, District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
Principal Investigator: Christopher A Attinger, MD Georgetown University
  More Information

Responsible Party: Christopher Attinger, M.D., Director of Center for Wound Healing, Georgetown University Identifier: NCT01252836     History of Changes
Other Study ID Numbers: 2010-160
Study First Received: December 1, 2010
Last Updated: December 14, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data was not collected for use in future research and will not be shared. processed this record on August 18, 2017